Equities

Sinphar Pharmaceutical Co Ltd

1734:TAI

Sinphar Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)32.85
  • Today's Change0.05 / 0.15%
  • Shares traded295.49k
  • 1 Year change+9.50%
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of TWD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,0811,2441,245
Total Receivables, Net643685593
Total Inventory839737697
Prepaid expenses79107158
Other current assets, total5.754.8610
Total current assets2,6492,7782,703
Property, plant & equipment, net3,2783,2043,247
Goodwill, net------
Intangibles, net7287117
Long term investments222520
Note receivable - long term------
Other long term assets603958
Total assets6,2516,1856,221
LIABILITIES
Accounts payable291324201
Accrued expenses------
Notes payable/short-term debt400447587
Current portion long-term debt/capital leases515061
Other current liabilities, total463625685
Total current liabilities1,2051,4461,534
Total long term debt1,4941,4161,486
Total debt1,9451,9132,134
Deferred income tax------
Minority interest300287355
Other liabilities, total154107123
Total liabilities3,1533,2553,499
SHAREHOLDERS EQUITY
Common stock1,6771,6771,677
Additional paid-in capital924930964
Retained earnings (accumulated deficit)634444211
Treasury stock - common------
Unrealized gain (loss)(44)(41)(37)
Other equity, total(93)(81)(92)
Total equity3,0982,9302,722
Total liabilities & shareholders' equity6,2516,1856,221
Total common shares outstanding168168168
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.